James Zacny to Risk Assessment
This is a "connection" page, showing publications James Zacny has written about Risk Assessment.
Connection Strength
0.039
-
Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors. Am J Clin Oncol. 2019 05; 42(5):413-420.
Score: 0.024
-
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain. 2012 Dec; 153(12):2315-2324.
Score: 0.015